CClinicalTrials.gg
CompletedNCT00200863Updated Aug 12, 2014

Effects of Different Colors of Light on Human Physiology

An interventional study of Monochromatic visible light exposure in Healthy and Circadian Rhythm, sponsored by Brigham and Women's Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-12.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This study will determine which color of light is most effective in stimulating a range of biological functions in humans including activation of sleep-wake regulatory system (alertness, performance, microsleeps, brain activity), activation of the nervous system (heart rate, temperature, blood pressure, breathing rate), and shifting the timing of the internal 24-hour (circadian) pacemaker.

Read the detailed description

Light has long been proposed to have a stimulatory effect on a range of biological functions in humans including increased feelings of activation, such as improved alertness or ability to perform. The mechanisms underlying how light stimulates these neurobiological systems remain to be elucidated. We propose to investigate the effects of different colors of light on human physiology, and in particular, test the claims that specific colors of light preferentially stimulate neurobiological, physiological and hormonal systems. Using classical photobiological techniques, we will construct action spectra for the effects of different colors of light on a range of non-image forming responses in humans.

We will test the hypotheses that: 1) light-induced activation of the neurobiological sleep-wake regulatory system, as indicated by increased alertness, faster reaction time, suppression of EEG alpha activity, microsleeps and slow rolling eye movements, and suppression of pineal melatonin, is most sensitive to retinal exposure to short wavelength blue light (460 nm) compared to equal photons of other colors of visible light; 2) light-induced activation of autonomic and hypothalamic-pituitary-adrenal axis measures of arousal, as indicated by increased heart rate variability, core body temperature, blood pressure, respiration rate, plasma cortisol levels and urinary catecholamines, is most sensitive to exposure to short wavelength blue light (460 nm) compared to equal photons of other colors; 3) phase shifts of the human circadian pacemaker, as assessed by changes in temperature, melatonin and cortisol rhythms, are most sensitive to exposure to short wavelength blue light (460 nm) compared to equal photons of other colors. The resultant action spectra will help to identify the photoreceptor mechanism(s) by which light activates arousal and circadian resetting, these non-image-forming physiological responses and enable us to distinguish between major candidate photoreceptive mechanisms, including potential novel photoreceptor systems, that might mediate such responses.

02

Conditions studied

  • Healthy
  • Circadian Rhythm

Keywords

  • light
  • wavelength
  • action spectrum
  • circadian
  • melatonin
  • alertness
  • performance
  • arousal
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Free from any acute, chronic or debilitating medical, psychological, or ophthalmological conditions
  • Drug-free (including caffeine, nicotine, and alcohol) for entire study duration

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol dependency
  • History of psychiatric illnesses or evidence of psychopathology according to standardized questionnaires, or in a structured clinical interview
  • Night shift work during the past 3 years
  • Transmeridian travel in the last 3 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    1

    420 nm light

    Device: Monochromatic visible light exposure

  • Experimental
    2

    480 nm

    Device: Monochromatic visible light exposure

  • Experimental
    3

    507 nm

    Device: Monochromatic visible light exposure

  • Experimental
    4

    555 nm

    Device: Monochromatic visible light exposure

  • Experimental
    5

    620 nm

    Device: Monochromatic visible light exposure

  • Experimental
    6

    460 nm

    Device: Monochromatic visible light exposure

Interventions

  • DeviceMonochromatic visible light exposure

    Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours

06

What researchers measure

Primary outcomes

  1. Subjective alertness prior to, during and after light exposure

    Time frame: 9.5 hours

  2. Auditory psychomotor performance prior to, during and after light exposure

    Time frame: 9.5 hours

  3. EEG power frequency prior to, during and after light exposure

    Time frame: 9.5 hours

  4. Plasma melatonin and cortisol prior to, during and after light exposure

    Time frame: 60 hours

  5. Heart rate, blood pressure, respiration rate and temperature prior to, during and after light exposure

    Time frame: 9.5 hours

  6. Urinary catecholamines prior to, during and after light exposure

    Time frame: 32 hours

07

Study locations

1 site
  • Division of Sleep Medicine, Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
08

References and documents

Publications

  • Gooley JJ, Chamberlain K, Smith KA, Khalsa SB, Rajaratnam SM, Van Reen E, Zeitzer JM, Czeisler CA, Lockley SW. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab. 2011 Mar;96(3):E463-72. doi: 10.1210/jc.2010-2098. Epub 2010 Dec 30. PubMed 21193540 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00200863
Lead sponsor
Brigham and Women's Hospital
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Responsible party
Steven W. Lockley (Neuroscientist, Brigham and Women's Hospital) — Principal investigator
First posted
Sep 20, 2005
Start date
Apr 2005
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Aug 12, 2014

Study contacts

Steven W Lockley, Ph.D.
principal investigator · Brigham and Women's Hospital, Harvard Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion